Texas Commits $50 Million to Largest State-Funded Ibogaine Clinical Trial After Drug Companies Fail to Meet Partnership Terms
Texas will fully fund a $50 million ibogaine trial through 11 universities after no drug company met partnership terms, targeting PTSD, addiction, and TBI in veterans.
Overview
Texas Lt. Gov. Dan Patrick and House Speaker Dustin Burrows announced in late March 2026 that the state will fully fund a $50 million ibogaine clinical trial program after multiple pharmaceutical companies failed to meet the legislature’s requirements for a public-private partnership. The decision transforms what was originally designed as a cost-sharing arrangement into the largest state-funded psychedelic clinical trial in the United States, led by a consortium of 11 Texas universities and medical centers known as IMPACT — Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma.
The two-year, multicenter trial will be led by UTHealth Houston and the University of Texas Medical Branch at Galveston (UTMB Health), targeting veterans and first responders suffering from addiction, post-traumatic stress disorder, and traumatic brain injury, according to an announcement from UTHealth Houston.
Why the State Took Over
Texas Senate Bill 2308, signed by Gov. Greg Abbott in 2025, originally allocated $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a pharmaceutical company. To qualify, companies were required to present an FDA approval plan, establish a corporate presence in Texas, match the state’s $50 million investment, and commit 20 percent of future drug sales revenue to the state.
No company met all four conditions. Patrick and Burrows announced that Texas would proceed without a private-sector partner, redirecting the full appropriation to the university-led IMPACT consortium. “We intend to fully fund this program,” Patrick said at the announcement.
The IMPACT Consortium
The consortium spans a broad cross-section of Texas research institutions. In addition to the two lead institutions, IMPACT includes Texas Tech University, Texas Tech University Health Sciences Center El Paso, the University of Texas at Austin, UT Health Science Center at San Antonio, UT Tyler, UT Rio Grande Valley, Texas A&M University, the University of North Texas Health Science Center, Baylor College of Medicine, and JPS Health Network in Dallas, as outlined in the UTHealth Houston announcement.
Research responsibilities are divided by institutional expertise. UTHealth Houston and UTMB will focus on ibogaine’s effects on addiction and associated conditions. UT Austin and Baylor College of Medicine will concentrate on traumatic brain injury, particularly among veterans with histories of blast exposure.
“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives,” said Dr. Melina Kibbe, president of UTHealth Houston. Dr. Kathryn A. Cunningham of UTMB Health added that “Texas will be at the forefront of the development of these medications for use in the United States.”
The consortium’s long-term goal is to generate the clinical data necessary for the FDA to reclassify ibogaine as an approved prescription medicine. Investigators are preparing Investigational New Drug applications and seeking Breakthrough Therapy designation from the agency.
The Stanford Study That Built the Case
The legislative push for ibogaine research traces in large part to a Stanford Medicine study published in Nature Medicine in January 2024. The observational study tracked 30 U.S. special operations veterans with traumatic brain injuries and repeated blast exposures who had independently sought ibogaine treatment at a clinic in Mexico. Nearly all participants were experiencing clinically severe psychiatric symptoms and functional disabilities at baseline.
One month after receiving ibogaine combined with magnesium — a protocol designed to mitigate ibogaine’s known cardiac risks — participants showed an average 88 percent reduction in PTSD symptoms, an 87 percent reduction in depression, and an 81 percent reduction in anxiety, according to Stanford Medicine. Scores on the World Health Organization Disability Assessment Schedule dropped from an average of 30.2, indicating moderate disability, to 5.1, indicating no disability. No serious cardiac events or unexpected adverse effects were reported.
“No other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury,” said Dr. Nolan Williams, associate professor of psychiatry and behavioral sciences at Stanford, who led the research. Formal cognitive testing also revealed measurable gains in concentration, information processing, memory, and impulsivity control.
What Ibogaine Is
Ibogaine is a psychoactive alkaloid derived from the root bark of the iboga shrub, a plant native to Central Africa. It interacts with multiple neurotransmitter systems simultaneously — including serotonin, dopamine, opioid, and glutamate receptors — which researchers believe accounts for its broad therapeutic profile across addiction, mood disorders, and neurological injury.
The compound remains classified as a Schedule I controlled substance under U.S. federal law, meaning it is currently illegal to manufacture, possess, or distribute. This classification has pushed most clinical use offshore, primarily to clinics in Mexico and Costa Rica. The Texas program aims to change that trajectory by generating rigorous, FDA-quality data within U.S. borders.
Ibogaine carries known cardiac risks, including the potential to cause fatal arrhythmias. The Stanford study’s use of magnesium co-administration as a cardioprotective measure has become the standard safety protocol, and the IMPACT consortium will require cardiac-monitored facilities for all trial participants.
A Growing State-Level Movement
Texas is not alone in pursuing ibogaine research through state funding. Arizona allocated $5 million for ibogaine clinical trials in its fiscal year 2026 budget, signed into law in late June 2025. That program originated from House Bill 2871, introduced by Rep. Justin Wilmeth, and is expected to be matched with private-sector funding for a total of $10 million.
Former Texas Gov. Rick Perry now chairs Americans for Ibogaine, an advocacy group that has described the combined state efforts as a potential “Manhattan Project” for the drug. Former Sen. Kyrsten Sinema has also backed the research, stating that “ibogaine has shown incredible results for special forces veterans.”
The federal government has signaled its own interest. The DEA’s proposed production quotas for 2026 call for 40,000 grams of psilocybin, up from 8,000 grams in 2023, alongside increased quotas for MDMA and methylone to support clinical trials for depression and PTSD. While those quotas cover different psychedelic compounds, they reflect a broader regulatory opening that could benefit ibogaine’s path to approval.